cytarabine has been researched along with panobinostat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SD; Buck, SA; Caldwell, JT; Chen, W; Drenberg, C; Edwards, H; Ge, Y; Inaba, H; Taub, JW; Xie, C; Xu, X | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C; Zhao, J | 1 |
| Bhalla, KN; Birdwell, CE; Das, K; Daver, N; Davis, JA; DiNardo, CD; Fiskus, W; Kadia, TM; Kantarjian, H; Loghavi, S; McGeehan, GM; Mill, CP; Ruan, X; Sasaki, K; Su, X; Takahashi, K | 1 |
2 trial(s) available for cytarabine and panobinostat
| Article | Year |
|---|---|
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BRCA1 Protein; Checkpoint Kinase 1; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Agonism; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Heterografts; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Panobinostat; Protein Kinases; Rad51 Recombinase; U937 Cells | 2013 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
2 other study(ies) available for cytarabine and panobinostat
| Article | Year |
|---|---|
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Cell Cycle; Checkpoint Kinase 1; Cytarabine; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Rad51 Recombinase; RNA Interference; Signal Transduction; THP-1 Cells; Transfection | 2017 |
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Topics: Aged; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Nuclear Proteins; Nucleophosmin; Panobinostat | 2023 |